Last reviewed · How we verify
NCT03725410
Multi-polar RF and PEMF for Treatment of Symptoms Associated With Vulvovaginal Atrophy
NA trial testing Venus Fiore Study Treatment in Vulvovaginal Atrophy in 81 participants. Completed in 31 December 2022.
30 September 2022
Quick facts
| Lead sponsor | Venus Concept |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | single group |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 81 |
| Start date | 25 September 2018 |
| Primary completion | 30 September 2022 |
| Estimated completion | 31 December 2022 |
| Sites | 2 locations across Italy, Spain |
Drugs / interventions tested
- Venus Fiore Study Treatment
- Venus Fiore Sham Treatment
Conditions studied
- Vulvovaginal Atrophy — all drugs for Vulvovaginal Atrophy →
Sponsor
Venus Concept
Who can join
19 and older, female only, with Vulvovaginal Atrophy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a multicenter, single-blind, randomized, sham-controlled study utilizing the Venus Fiore™ (MP)2, a table-top device designed to deliver multi-polar RF energy and pulsed electromagnetic fields for use in dermatological and general surgical procedures to temporarily improve blood circulation and to induce modification of collagen structure, neocollagenesis and angiogenesis for the treatment of symptoms associated with vulvovaginal atrophy.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03725410
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Vulvovaginal Atrophy
Currently open trials in the same condition.
- NCT05562518 — GRACE-trial: a Randomized Active-controlled Trial for vulvovaGinal atRophy in breAst Cancer Patients on Endocrine Therap · Phase 4 · active not recruiting
Other Venus Concept trials
Trials by the same sponsor.
- NCT05897723 — Fractional Radiofrequency for Reduction of Surgical Scar Formation · NA · unknown
- NCT05091788 — Robotic Mechanical Coring for the Treatment of Moderate to Severe Facial Wrinkles · NA · unknown
- NCT05256771 — Electrical Muscle Stimulation with 1064 Nm Diode Laser and RF/PEMF for Non-invasive Body Contouring and Fat Reduction. · NA · active not recruiting
- NCT04827680 — Clinical Evaluation of the Safety and Performance of FRF for the Treatment and Reduction of Acne Scarring · NA · completed
- NCT04910945 — Mechanical Coring to Achieve Directional Skin Tightening · NA · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03725410 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Venus Concept
- Last refreshed: 2 June 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03725410.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing